Quality not sufficient samples on next-generation sequencing platforms analyzed on MassARRAY® and actionable mutations were identified. BETHESDA, Md., Nov. 20, 2024 /PRNewswire/ -- Precision for Medicine, a leading next-generation provider of drug development research and services, today announced a strategic partnership with Agena Bioscience that helps bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. Precision for Medicine and Agena Bioscience will present cutting-edge findings on profiling challenging lung tumor samples at the Association for Molecular Pathology (AMP) 2024 Annual Meeting Expo, held November 19-23, 2024. Precision for Medicine's robust biospecimen inventory played a pivotal role in this study, which utilized lung tumor samples previously deemed quality not sufficient (QNS) or failed on NGS platforms. With Agena Bioscience's advanced MassARRAY® technology and Precision for Medicine's deeply characterized samples, actionable mutations were identified in 40% of cases, showcasing the transformative potential of this collaboration and advanced analytical capabilities

Breakthrough Spatial Biology Solutions Accelerate Immuno-Oncology (IO) Drug Discovery and Development. BETHESDA, Md., Nov. 6, 2024 /PRNewswire/ -- Precision for Medicine, a leading next-generation provider of drug development and commercialization services, today announced the integration of Akoya's PhenoCycler-Fusion 2.0 and early access for the new PhenoCode Discovery IO60 immuno-oncology panel into its service portfolio. Precision for Medicine now offers services based on both the PhenoCycler and PhenoImager® platforms, enabling a seamless continuum from biomarker discovery through application in the clinical trial setting. The PhenoCycler-Fusion 2.0 is a next-generation ultrahigh-plex and high-throughput spatial biology solution that combines automated fluidics with high-speed imaging to generate high-resolution images of multiple biomarkers on tissue sections. This platform enables the simultaneous analysis of hundreds of biomarkers, providing a comprehensive understanding of tumor biology and immune interactions